SNDL Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.03-19

SNDL (NASDAQ:SNDL) Full Year 2024 Results

Key Financial Results

  • Revenue: CA$920.4m (up 1.3% from FY 2023).
  • Net loss: CA$94.8m (loss narrowed by 44% from FY 2023).
  • CA$0.36 loss per share (improved from CA$0.65 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

NasdaqCM:SNDL Earnings and Revenue Growth March 19th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

SNDL EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 6.0% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for SNDL that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment